ATE530196T1 - Menschliches anthrax-toxin neutralisierende monoklonale antikörper und verfahren zu deren anwendung - Google Patents

Menschliches anthrax-toxin neutralisierende monoklonale antikörper und verfahren zu deren anwendung

Info

Publication number
ATE530196T1
ATE530196T1 AT05780195T AT05780195T ATE530196T1 AT E530196 T1 ATE530196 T1 AT E530196T1 AT 05780195 T AT05780195 T AT 05780195T AT 05780195 T AT05780195 T AT 05780195T AT E530196 T1 ATE530196 T1 AT E530196T1
Authority
AT
Austria
Prior art keywords
monoclonal antibodies
neutralizing monoclonal
anthrax toxin
toxin neutralizing
human anthrax
Prior art date
Application number
AT05780195T
Other languages
English (en)
Inventor
Herman Groen
Christine Cool-Kebbedies
Kunja Slopsema
Hans Westra
Original Assignee
Iq Therapeutics Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iq Therapeutics Bv filed Critical Iq Therapeutics Bv
Application granted granted Critical
Publication of ATE530196T1 publication Critical patent/ATE530196T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1278—Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT05780195T 2004-03-03 2005-03-03 Menschliches anthrax-toxin neutralisierende monoklonale antikörper und verfahren zu deren anwendung ATE530196T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54964104P 2004-03-03 2004-03-03
PCT/IB2005/002495 WO2005120567A2 (en) 2004-03-03 2005-03-03 Human anthrax toxin neutralizing monoclonal antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE530196T1 true ATE530196T1 (de) 2011-11-15

Family

ID=35276110

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05780195T ATE530196T1 (de) 2004-03-03 2005-03-03 Menschliches anthrax-toxin neutralisierende monoklonale antikörper und verfahren zu deren anwendung

Country Status (7)

Country Link
US (2) US7658925B2 (de)
EP (2) EP2163257A1 (de)
AT (1) ATE530196T1 (de)
AU (1) AU2005251535A1 (de)
CA (1) CA2560759A1 (de)
ES (1) ES2376337T3 (de)
WO (1) WO2005120567A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002046228A2 (en) * 2000-12-05 2002-06-13 Wisconsin Alumni Research Foundation Receptor for b. anthracis toxin
WO2004052277A2 (en) * 2002-12-05 2004-06-24 Wisconsin Alumni Research Foundation Anthrax antitoxins
BRPI0410562B8 (pt) 2003-05-22 2021-05-25 Fralunhofer Usa Inc proteína de veículo e seu método de produção em uma planta, ácido nucleico isolado, vetor de expressão e célula hospedeira
US20060246079A1 (en) * 2003-11-14 2006-11-02 Morrow Phillip R Neutralizing human antibodies to anthrax toxin
ATE530196T1 (de) * 2004-03-03 2011-11-15 Iq Therapeutics Bv Menschliches anthrax-toxin neutralisierende monoklonale antikörper und verfahren zu deren anwendung
US7838252B2 (en) * 2005-02-17 2010-11-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating a subject having an anthrax toxin mediated condition
KR100694508B1 (ko) * 2005-05-24 2007-03-13 울산대학교 산학협력단 Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법
CA2616859C (en) 2005-08-03 2015-04-14 Fraunhofer Usa, Inc. Compositions and methods for production of immunoglobulins
US20070202117A1 (en) * 2005-12-22 2007-08-30 Herman Groen Compositions and Methods Of Modulating the Immune Response
US20090280130A1 (en) * 2006-06-14 2009-11-12 Children's Medical Center Corporation Method for the treatment of anthrax toxicity
GB0612456D0 (en) * 2006-06-23 2007-03-28 Secr Defence Antibody for anthrax
CN101680026A (zh) * 2007-01-12 2010-03-24 康乃尔研究基金会有限公司 作为真核病原体感染治疗的新型靶的腺苷酰环化酶
WO2008121171A1 (en) * 2007-01-12 2008-10-09 Cornell Research Foundation, Inc. Adenylyl cyclases as novel targets for antibacterial interventions
EP2463304B1 (de) 2007-02-23 2014-04-30 The United States of America as represented by the Secretary, Department of Health and Human Services Monoklonale Antikörper zur Neutralisierung von Anthrax-Toxinen
KR100868248B1 (ko) 2007-03-13 2008-11-12 한양대학교 산학협력단 탄저 감염 진단용 신규한 펩타이드 탐침
WO2009009759A2 (en) 2007-07-11 2009-01-15 Fraunhofer Usa, Inc. Yersinia pestis antigens, vaccine compositions, and related methods
GB0809474D0 (en) * 2008-05-27 2008-07-02 Prendergast Patrick T Comosition and method for teh assay and treatment of anthrax
US8734803B2 (en) 2008-09-28 2014-05-27 Ibio Inc. Humanized neuraminidase antibody and methods of use thereof
US8343495B2 (en) * 2009-01-10 2013-01-01 Auburn University Equine antibodies against Bacillus anthracis for passive immunization and treatment
US20110129460A1 (en) * 2009-01-14 2011-06-02 IQ Therapeutics B.V. Combination Antibodies For The Treatment And Prevention Of Disease Caused By Bacillus Anthracis And Related Bacteria And Their Toxins
EP2387584A1 (de) * 2009-01-14 2011-11-23 IQ Therapeutics BV Kombinierte antikörper zur behandlung und vorbeugung von durch bacillus anthracis, entsprechenden bakterien und deren toxinen hervorgerufenen erkrankungen
US8784819B2 (en) 2009-09-29 2014-07-22 Ibio Inc. Influenza hemagglutinin antibodies, compositions and related methods
GB2480298A (en) * 2010-05-13 2011-11-16 Secr Defence Antibodies against Bacillus anthracis
WO2018210896A1 (en) * 2017-05-19 2018-11-22 F. Hoffmann-La Roche Ag Method for the production of thymocyte supernatant
KR102490823B1 (ko) * 2020-07-27 2023-01-20 국방과학연구소 탄저균 보호항원에 특이적인 인간화 항체 및 이의 제조방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5030719A (en) 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
EP1005870B1 (de) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierungs-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyten beschränkt ist, für die Behandlung von B-Zell-Lymphoma
EP1189931B1 (de) * 1999-07-02 2006-06-21 Genentech, Inc. An her2 bindende peptidverbindungen
AU2002254482A1 (en) * 2001-03-19 2002-10-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of kidney cancer
US7262019B2 (en) * 2001-05-03 2007-08-28 Immunetics, Inc. System and methods for detection of Bacillus anthracis related analytes in biological fluids
GB0126266D0 (en) * 2001-11-01 2002-01-02 Microbiological Res Authority Anthrax antigenic compositions
EP1572903A2 (de) * 2002-02-11 2005-09-14 Alexion Pharmaceuticals, Inc. Immuntherapeutika zur bioabwehr
US20040258699A1 (en) * 2002-02-11 2004-12-23 Bowdish Katherine S. Immunotherapeutics for biodefense
MXPA05012571A (es) 2003-05-21 2006-02-08 Medarex Inc Anticuerpos monoclonales humanos contra el antigeno protector de bacillus anthracis.
CA2545714C (en) * 2003-11-14 2012-10-16 Avanir Pharmaceuticals Neutralizing human antibodies to anthrax toxin generated by recall technology
WO2005081749A2 (en) * 2004-01-23 2005-09-09 Avanir Pharmaceuticals, Inc. Neutralizing human antibodies to anthraxtoxin
ATE530196T1 (de) * 2004-03-03 2011-11-15 Iq Therapeutics Bv Menschliches anthrax-toxin neutralisierende monoklonale antikörper und verfahren zu deren anwendung

Also Published As

Publication number Publication date
AU2005251535A1 (en) 2005-12-22
EP2163257A1 (de) 2010-03-17
US20060258842A1 (en) 2006-11-16
US20110059098A1 (en) 2011-03-10
EP1729806A2 (de) 2006-12-13
WO2005120567A2 (en) 2005-12-22
US7658925B2 (en) 2010-02-09
WO2005120567A3 (en) 2006-03-30
ES2376337T3 (es) 2012-03-13
EP1729806B1 (de) 2011-10-26
CA2560759A1 (en) 2005-12-22

Similar Documents

Publication Publication Date Title
ATE530196T1 (de) Menschliches anthrax-toxin neutralisierende monoklonale antikörper und verfahren zu deren anwendung
WO2021222935A3 (en) Neutralizing anti-sars-cov-2 antibodies and methods of use thereof
DE60142410D1 (de) Immunomodulatorische polynukleotide und verfahren zur deren verwendung
ATE544772T1 (de) Immunstimulierende sequenz-oligonukleotide und verwendungsverfahren dafür
TW200618810A (en) Treatment of respiratory syncytial virus (RSV) infection
CY1110783T1 (el) Μονοκλωνικα αντισωματα κατα αυξητικου παραγοντα ηπατοκυτταρων
ATE423571T1 (de) Verwendung von bispezifischen antikörpern gegen einen aktivierenden rezeptor fcepsilonri und gegen einen inhibierenden rezeptor ox2ra (cd200ra) zur regulierung der immunantworten
DE60135251D1 (de) Trokar-zugvorrichtung und verfahren
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
CY1110188T1 (el) Αντισωματα κατα συζυγων φωσφορυλχολινης
DE60217597D1 (de) Gerät und Verfahren zur Personenerkennung
EP1816990A4 (de) Systeme, vorrichtungen und verfahren zur behandlung von bandscheibenerkrankungen
ATE485057T1 (de) Humanisierte antikörper gegen cd40 und verfahren zu ihrer anwendung
EP1626730A4 (de) Verfahren, gerät und zusammensetzung zur behandlung von akne
DE60234674D1 (de) Verfahren, Program und Gerät zur Authentifizierung
DK1212422T3 (da) Humane CTLA-4-antistoffer og anvendelserne deraf
EP4019343A4 (de) Verfahren und vorrichtung für insassenschutz
DE602006007808D1 (de) Vorrichtung, verfahren und verwendung zur behandlung von neuropathie mit stickoxid
EP2394658A3 (de) Passive Immunisierung gegen Clostridium difficile-Erkrankung
EP2079430A4 (de) Verfahren und system zur verbesserung der sensorischen, reflex- und/oder motorischen mechanismen einer person durch auditorische, taktile oder visuelle stimulierungen
DE602004015456D1 (de) Patiententemperatur-wiederholungssystem und verfahren
WO2009154995A3 (en) Interleukin 10 receptor (il-10r) antibodies and methods of use
DK2109623T3 (da) Cancerbehandling med anti-IL-1-antistoffer
EP4301226A4 (de) Kopfmontierbare okulomotorische beurteilungsvorrichtung und system sowie verfahren zur verwendung davon
EP4193105C0 (de) Rauchgasbehandlungsvorrichtung und entsprechendes verfahren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties